Summary. Since cyelosporin A (CsA) is an immunosuppressive agent, its beneficial effect in psoriasis suggests that immune cells may play a role in the pathogenesis and resolution of psoriasis. To determine early effects of CsA in psoriasis, we quantitated immune cells using double immunofluorescence microscopy on biopsy specimens obtained prior to therapy and after 3,7, and 14 days of CsA therapy. CsA therapy resulted in significant reductions in the absolute number of immune cells (including T cells, monocytes[macrophages, and antigen presenting cells) contained within psoriatic skin. The effect was rapid, with over one-half of the reduction in the density of HLel § (human leukocyte antigen-1 positive or bone marrow derived) cells, including T cells, activated T cells, monocytes, and Langerhans cells (LCs), occurring within 3 days. Despite the overall reduction in the numbers of immunocytes in the skin, the proportion of T cells, Langerhans cells, and monocytes in relation to the total number of immune cells was unchanged with therapy, reflecting equally proportional losses of each subtype. Dermal CD1 +DR + cells (putative Langerhans cells), which are not found in normal skin but are present in lesional psoriasis skin, were virtually cleared from the papillary dermis after CsA therapy. Although absolute numbers of epidermal Langerhans cells, defined as cells expressing both CD1 (T6) and DR molecules (CD1 + DR +), were also reduced after CsA, epidermal non-Langerhans CD1-DR + cells (macrophages, activated T cells, DR-keratinocytes) demonstrated a proportionally greater decrease, with the ratio of CDI+DR + Langerhans cells]non-Langerhans CD1-DR + epidermal cells changing from a mean of 0.82 at baseline to 1
Psoriasis is a common inflammatory disorder, probably of multifactorial etiology, affecting approximately 2% of the population in the United States of America. We recently carried out a randomized, double-blind trial in which cyclosporine A (CsA), administered at a dose of 14 mg/kg/day, caused dramatic improvement in 20 of 21 psoriatic patients within 4 weeks [1] . Since CsA has immunosuppressive effects, this raised the possibility that cellular immune processes may play a role in the pathophysiology of psoriasis. Analysis of changes in immune cellular elements present in lesional psoriasis skin may help elucidate the mechanism of action of CsA in psoriasis.
In six consecutive patients, we performed quantitative single and double immunofluorescence microscopy using monoclonal antibodies directed toward leukocyte subsets in order to characterize immune cellular changes that occur within the epidermal and dermal infiltrate at various times after initiation of oral CsA therapy. Baker et al. [2] have looked at changes in immune cell types in psoriatic lesions treated with CsA at time intervals ranging between 10 and 90 days after CsA therapy. Since we saw clinical improvement in most patients by 10 days of CsA therapy (14 mg/kg/day) [I], we decided to investigate the changes in immune cell types prior to clinical improvement being obvious. In addition, we correlated clinical improvement with the nature and flux of the infiltrate. Here, we report that CsA induces changes in activated T cells, antigen presenting cells (APCs) and monocytes, expressed as both absolute density of cells in the tissue and as relative percentages of total leukocytes within 7 days of CsA therapy.
Materials and methods

Patients
Six consecutive patients (all males), treated with CsA 14 mg/kg/ day for 4 weeks, were studied for immunophenotype analysis. Their mean age was 45 years (range, 32 to 61 years). Patients had greater than 20% body surface area involved and had been unresponsive to conventional therapies. The psoriasis had been stable in extent and severity for at least 2 weeks. The patients had not used systemic or intralesional corticosteroids, or ultraviolet (UVB or PUVA) therapy for at least 4 weeks, nor topical therapy, except bland emmolients, for at least 2 weeks prior to entry into the study. Patients were at least 18 years old and in good health on the basis of history and physical examination. Clinical evaluation of psoriasis was made at pretherapy, after the 3rd and 7th days of therapy, and then at weekly intervals.
The protocol and consent had been approved by the University of Michigan Medical Center institutional review board. The Food and Drug Administration had approved our physician's investigational drug application. All the patients gave informed consent after the nature of the study had been fully explained.
the primary antibody (first step) which was visualized with rhodamine-conjugated goat anti-mouse IgG (second step) and then a second directly fluoresceinated antibody to a separate determinant was mixed with normal mouse serum and applied to the tissue (third step). The mouse serum prevents binding of the rhodamine goat anti-mouse IgG antibody to the third step antibody. The sections were coverslipped in PBS containing 50% glycerol and visualized using a Nikon Optiphot microscope equipped with epifluorescence, appropriate filters, and double exposure photographic capabilities. For each specimen, the density of cells stained by the various monoclonal antibodies was counted in at least 10 high power fields (hpf; 1.4 linear mm of skin) and the average obtained. When sections stained with anti-CD1 antibody were examined, only dendritic cells exhibiting the cytoplasm and nucleus were counted as positive; dendrites without the main cell body were not included [19] .
Statistical evaluation
In order to determine whether the degree of infiltrate (absolute density per mm) of the various phenotypes had changed significantly between baseline and days 3 and 7, a paired t-test was used. This test was also used to evaluate whether the phenoffpes Monol, Leul, Leul+DR +, CDI+DR +, and CD1-DR + expressed as a ratio of HLel +, had changed significantly between baseline and day 7. We also determined, using Pearson's correlation analysis, whether there was a relationship between clinical lesion scores and a change in certain cell phenotypes. Allp values are two-sided unless otherwise stated.
Fluorescence microscopy
In 3 patients, 6-mm punch biopsy specimens were taken from representative psoriatic plaques at pretherapy and after 3 and 7 days of CsA therapy, and in three patients at pretherapy and after 7 and 14 days. Punch biopsy specimens were obtained following local anesthesia with 1% lidocaine with epinephrine. These were embedded in Tissue Tek II O.C.T. compound (Miles Laboratories, Naperville, Ill.) and were rapidly frozen and stored at -70 ~ C. Subsequently, 6-1am sections were cut on a cryostat, mounted on albuminized slides, and air dried.
In order to determine the type and intensity of the epidermal and dermal infiltrate, a battery of monoclonal antibodies was employed. HLel is a surface antigen expressed on all human bone marrow derived cells (leukocytes; Becton Dickinson, Mountainview, Calif). Leul detects a pan T cell antigen (CD5) on human peripheral and thymic T cells (Becton Dickinson). OKT6 stains the cell-surface antigen CD 1 on cortical thymocytes and Langerhans cells (LCs; Ortho Diagnostic Systems). Anti HLA-DR (Becton Dickinson) binds to class II major histocompatibility complex proteins of LCs, B cells, activated T cells, monocytes, and interferon gamma-exposed keratinocytes. Monol is a monocyte antigen marker (Bethesda Research Laboratories (BRL), Bethesda, Md.).
For single label immunofluorescence, 6-~tm frozen sections of psoriatic tissue were incubated with optimal dilutions of the primary antibody for 45 min at room temperature, washed three times in phosphate-buffered saline (PBS) at pH 7.6, followed by a 30-min incubation with second step fluorescein-conjugated antibody (goat anti-mouse IgG antibody, heavy and light chain specific, affinity purified and human serum adsorbed; Kirkegaard and Perry, Gaithersburg, Md.). For double label immunofluorescence microscopy, one primary antibody was fluoreseein-conjugated and the other primary antibody was biotin-conjugated. The second step reagent was Texas Red conjugated to streptavidin (Bethesda Research Laboratories). In some cases, a three-step method was used, which consisted of
Results
The mean number of cells/hpf in the epidermis and dermis of the six patients at days 0 (baseline) and 7 of CsA therapy is shown in Figs. 1 and 2 respectively. Lesional psoriasis skin contained a large number and variety of infiltrating leukocytes. In addition to LCs, non-Langerhans CD1 -DR + cells were present in psoriasis epidermis (Fig. 3a, b) . HLel + cells (bone marrow-derived leukocytes) were present in the epidermis and dermis, and were comprised of Leul + T cells (Fig. 4a, b) , activated (DR +) T cells (Fig. 5a, b ) and monocyte/macrophage derived cells (Fig. 5 c) .
CsA therapy resulted in a marked decrease in these cell types from the skin (Figs. 4c, d and 5d-f). Absolute cell counts of each phenotype were performed to quantitate the degree of clearing (Figs. 1 and 2). Between days 0 and 7, in the epidermis, there was a significant decrease (p < 0.01) of bone marrow-derived cells, whether calculated as the number of HLel + cells or as the total of Leul, Monol and CD1 + DR + cells. There were also significant decreases in the number of HLel -DR + keratinocytes, Monol + macrophages, Leul + T cells, Leul+DR + activated T cells, CDI+DR + LCs and non-Langerhans CD1-DR + cells (Fig. 1) .
In the epidermis, HLel-DR + cells identify keratinocytes, presumably induced by gamma-interferon to express HLA-DR. These decreased by 47% (Figs. 2, 3) . As in the epidermis, significant reductions in the absolute numbers of infiltrating cells in the dermis were observed after CsA therapy. Compared with untreated psoriasis skin, the absolute numbers of dermal CD1 +DR + Langerhans cells decreased by 66% over the 1st week of CsA therapy, and by day 7 of therapy, these cells were rarely seen. Although the density of all T cells was reduced at day 7 (Fig. 2) , the mean percentage decrease of activated T cells (DR+Leul +) was only 30%, compared to a 66% decrease of nonactivated T cells ( D R -L e u + ; p < 0.05). Persistence of D R + L e u l + T cells was also observed in the epidermis.
If clearing of immunocytes from the skin is important to the mechanism of CsA action in psoriasis, then the cells should show a brisk response which is followed by clinical improvement. In order to assess the rapidity of disappearance of individual cell types, changes in the absolute numbers of cells/ hpf between pretherapy and days 3, 7, and 14 were expressed as the percent decrease in the absolute numbers of cells/hpf relative to day 0. For example, the percentage decrease in Leul cells at days 3, 7, and 14 of therapy were 42%, 49%, and 61% respectively. The majority of the loss of leukocytes (Leu 1 +, Mono I +, and C D 1 -D R +) occurred within the first 3 days of CsA therapy (mean decrease that occurred during the first 3 days expressed as a percentage of the decrease that had occurred during the first 14 days of therapy was 63 %). DR + keratinocytes (HLe 1 -DR +) demonstrated a somewhat slower decrease in the absolute numbers of cells per hpf relative to baseline of 30%, 52%, and 86% at days 3, 7, and 14 of CsA therapy respectively.
Clinical lesion scores demonstrated a 30%, 52%, and 70% decrease (relative to pretherapy) at days 3, 7, and 14, respectively, following CsA therapy. Thus, although it is difficult to compare clinical lesion score data with cellular immunopathology quantitations, it CDI+DR + LCs (Table1). For the phenotype CD1-DR + in the epidermis, there was a significant decrease (p = 0.04) in the number of cells of this subtype expressed as a percentage of total leukocytes between days 0 and 7 of therapy, confirming that LCs tended to emerge as the predominant DR + cell in treated epidermis (Table 1) .
Discussion
There is a marked difference in the composition of the various cell types in psoriatic epidermis and dermis compared with normal skin. Bone marrow derived cells in the normal human epidermis consist almost entirely of LCs [4] [5] [6] . These LCs normally comprise 1%-4% percent of the total epidermal population [5, 7] . In our untreated patients, leukocytes in the epidermis of involved psoriasis skin were composed of CDI +DR + LCs, Monol + macrophages and Leul + cells (Fig. 1) . In a study by Baker et al.
[10], epidermal leukocytes in psoriasis skin were also elevated and contained both T cells and DR + dendritic cells (CDI+DR + LCs and CD1-DR + epidermal cells).
Utilizing epidermal cell suspensions, we have previously shown that psoriatic epidermal cells contain an elevated capacity to activate T cells [8] . The CD1-DR + cells in psoriatic epidermis appear to be antigen presenting cells, since both CD1-DR + cells as well as CD1 +DR + LCs, were critical for the induction of T cell activation [8] . In the normal dermis, bone marrow derived cells are usually comprised of monocytes and macrophages [9] , as well as a small number of T cells [10] . We found that leukocytes in the dermis of psoriatic plaques consisted of approximately equal proportions of T cells and cells of the monocyte/ macrophage series, along with an increased proportion of CDI+DR + LCs (which are only rarely present in normal dermis). Other authors [11, 12] have also found that the dermal infiltrate in early and fully developed psoriatic lesions consists mostly of T~ lymphocytes and macrophages, with the former being the predominant cell type. CsA therapy caused a marked decrease in the intensity of the immunocytic infiltrate in both the epidermis and dermis. There was a significant decrease in the number of all subsets of leukocytes and in epidermal HLel-DR + keratinocytes. However, the proportion of T cells, activated T cells, monocytes, CD1 +DR + LCs and dermal CD1-DR + cells in relation to the total number of leukocytes was unchanged with therapy, reflecting equally proportionate losses of each subtype (Table I ). The reduction in the absolute numbers of total leukocytes, T cells, activated T cells, monocytes and CDI+DR § LCs was rapid, with a large proportion of the change occurring within 3 days. The rapidity of the CsA effect on leukocyte reduction is consistent with the concept that the immune effects of CsA are important in the mechanism of CsA clearing of psoriasis, since leukocyte reduction either preceded or coincided with clinical improvement.
In psoriatic epidermis, using double immunofluorescence techniques to visualize CD1 and HLA-DR, we found that the absolute numbers of LCs decreased with CsA therapy, with the number and pattern of LCs in treated psoriatic epidermis being similar to that of normal skin. Much attention has been focused on the number and location of LCs in psoriasis; however, it remains controversial as to whether LCs in psoriasis lesions as assessed in vertical sections are increased relative to normal [13] or uninvolved psoriasis skin [13, 14] , or decreased compared with normal [15, 16] or uninvolved psoriasis skin [14] . Comparison of epidermal LCs density obtained by various authors [14] [15] [16] [17] [18] [19] is difficult because of the large numbers of methods used to quantitate LCs in sections [2, 14, 15, 17, 20, 21] . Utilizing epidermal cell suspensions to quantitate CD1 +DR § LCs in relation to keratinocytes, we found no significant difference in the percentage of Langerhans cells in psoriasis epidermis relative to uninvolved epidermis [8] . As reported by Bos et al. [22] , we found that LCs are present in significantly increased numbers in the dermis in untreated lesions of psoriasis (Fig. 3) , since LCs are only rarely present in normal dermis [10, 231. The presence of dermal LCs in untreated psoriatic lesional skin supports the concept of psoriatic skin harboring a form of an ongoing cellular immune response. Significant numbers of dermal LCs are generally only found in the context of cellular immune responses in the skin (for example, allergic contact dermatitis) [24] or in cutaneous T-cell lymphoma [25] .
Unlike normal skin which lacks epidermal CD1-DR + ceils [8, 22] , in lesional psoriatic skin CDI-DR + cells were present in the epidermis at day 0. CD1-DR + cells in the epidermis of psoriatic skin are heterogenous [8] and contain a variety of DR § cells, including activated T cells (DR § T lymphocytes), activated keratinocytes (DR § keratinocytes), DR + monocytes and non-LCs dendritic APC [1, 8, 23] . CD 1 -DR § dendritic cells may contain immature LCs, since Birbeck granules have been found in certain of these cells [9] . However, psoriasis epidermal CDI-DR + cells may be analogous to nonLangerhans CD1-DR + cells, reported following UVB and UVC radiation, that are potent stimulators of immunoregulatory self-T cells in the absence of added antigen [26] [27] [28] [29] . In fact, Schopf et al. [30] have demonstrated that epidermal cells from lesional psoriatic skin are significantly more active in stimulating autologous T cell proliferation compared with cells from uninvolved psoriatic or normal epidermis. Since CD1-DR + epidermal cells are involved in the enhanced antigen presenting activity of psoriasis epidermal cells [8] , the CD1 -DR + population may be critical for initiating T-cell activation and inflammatory lymphokine release in psoriasis skin.
In the epidermis by day 7 of therapy, both the absolute numbers of CD1 -DR + cells (Fig. 1) as well as the proportion of these cells as a percentage of total leukocytes at day 7 was decreased (Table 1) . We also noted a dramatic loss of CDI -DR + cells as well as antigen presenting cell function, in psoriasis epidermis during CsA therapy when quantitated using epidermal cell suspensions [31] . Epidermal non-Langerhans CD1-DR + cells demonstrated a proportionally greater decrease compared to epidermal CDI +DR + LCs with the ratio of CDI+DR + LCs/nonLangerhans CD1-DR + epidermal cells changing from a mean of 0.82 to 1.92 at day 14. Thus, CsA appears to be effective at clearing CD1-DR + cells while leaving Langerhans cells relatively intact in the epidermis.
Our findings of a rapid reduction in T-cell numbers in psoriasis skin following CsA therapy are consistent with a role for T cells and their lymphokines in psoriasis. Double staining with anti-HLel and anti-HLA DR or anti-Leul and anti-HLA DR monoclonal antibodies confirmed that in lesional psoriatic epidermis, DR § keratinocytes are present in the vicinity ofT cells in a basilar position [18, 32] .
Psoriasis skin contains increased numbers of monocytes, Langerhans cells, and T cells, and shows evidence of an ongoing cellular immune reaction. CsA may cause improvement of psoriasis by interfering with immune cell activation in the skin. This is supported by the decreased numbers of inflammatory cells in both the epidermis and dermis, and evidence of reduced production of proinflammatory cytokines early in the course of treatment with CsA.
